Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Armand

Showing results (181-190 of 273) with videos related to

Pageof 28
Sort By:
The Lancet. Oncology|February 25, 2011
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation studyIrene M Ghobrial, Edie Weller, Ravi Vij, et al.
British Journal of Haematology|October 7, 2016
Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphomaAlex F Herrera, Haesook T Kim, Katherine A Kong, et al.
Blood|June 2, 2016
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicityBenjamin L Lampson, Siddha N Kasar, Tiago R Matos, et al.
JACC. Heart Failure|July 28, 2022
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With AnthracyclinesCarlos A Gongora, Zsofia D Drobni, Thiago Quinaglia Araujo Costa Silva, et al.
The Lancet. Oncology|July 25, 2016
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trialAnas Younes, Armando Santoro, Margaret Shipp, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 19, 2025
Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving ChemoimmunotherapyP Connor Johnson, Jeremy S Abramson, Ann S LaCasce, et al.
Blood|April 14, 2016
Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host diseaseJohn Koreth, Haesook T Kim, Kyle T Jones, et al.
The New England Journal of Medicine|December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaStephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.
Leukemia & Lymphoma|February 21, 2024
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOPRonald Nemec, Marielle Scherrer-Crosbie, Jeremy S Abramson, et al.
Haematologica|January 13, 2018
Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II resultsJohn Koreth, Haesook T Kim, Paulina B Lange, et al.
Pageof 28

Showing results (181-190 of 273) with videos related to

Sort By:
Pageof 28
The Lancet. Oncology|February 25, 2011
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation studyIrene M Ghobrial, Edie Weller, Ravi Vij, et al.
British Journal of Haematology|October 7, 2016
Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphomaAlex F Herrera, Haesook T Kim, Katherine A Kong, et al.
Blood|June 2, 2016
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicityBenjamin L Lampson, Siddha N Kasar, Tiago R Matos, et al.
JACC. Heart Failure|July 28, 2022
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With AnthracyclinesCarlos A Gongora, Zsofia D Drobni, Thiago Quinaglia Araujo Costa Silva, et al.
The Lancet. Oncology|July 25, 2016
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trialAnas Younes, Armando Santoro, Margaret Shipp, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 19, 2025
Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving ChemoimmunotherapyP Connor Johnson, Jeremy S Abramson, Ann S LaCasce, et al.
Blood|April 14, 2016
Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host diseaseJohn Koreth, Haesook T Kim, Kyle T Jones, et al.
The New England Journal of Medicine|December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaStephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.
Leukemia & Lymphoma|February 21, 2024
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOPRonald Nemec, Marielle Scherrer-Crosbie, Jeremy S Abramson, et al.
Haematologica|January 13, 2018
Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II resultsJohn Koreth, Haesook T Kim, Paulina B Lange, et al.
Pageof 28